Abstract 15885: Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters
Introduction: Cases of QT prolongation and other life-threatening arrhythmias have been reported with acute high volume energy drink (ED) usage. While caffeine doses under 400mg are not considered arrhythmogenic, the safety of the other ingredients in EDs need evaluation. This study evaluated the ECG and blood pressure effects of acute high volume ED consumption when compared to caffeine.
Methods: This was a double-blind, controlled, crossover study enrolling young healthy volunteers. Subjects randomly consumed a single 32oz dose of an ED (320 mg caffeine) and a matching caffeinated (320 mg) control drink separated by a 6-day washout period. A standard 12-lead ECG and blood pressure were obtained at baseline, 1, 2, 4, 6 and 24 hours post drink consumption. The intra-group change from baseline in the QTc, QT and PR intervals, QRS duration, systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were evaluated using the paired student’s t-test.
Results: Eighteen subjects (27±4 yrs) were included for analysis. A significant difference in the QTc interval was noted 2 hours post ED consumption when compared to the caffeine arm (0.44±18.4 vs -10.4±14.8 msec; p=0.036). SBP was significantly higher 6 hours post ED consumption when compared to the caffeine arm (4.72±4.67 vs 0.83±6.09 mmHg; p=0.016). A significant increase in HR was evident 2 hours post ED consumption when compared to the caffeine arm (3.39±11.0 vs -0.61±9.13 bpm; p=0.045). There were no time matched intra-group differences with the QT and PR intervals, QRS duration and DBP. The maximum and minimum intra-group change from baseline were no different for all endpoints (all p-values >0.195).
Conclusions: EDs did not reduce 2 hour post dosing QTc interval as observed with caffeine. ED consumption increased SBP and HR by 4 mmHg and 3 bpm, respectively when compared to caffeine. Ingredients other than caffeine in EDs warrant further investigation. The work reported herein was performed under United States Air Force Surgeon General approved Clinical Investigation Number FDG20130042H. The views expressed in this material are those of the authors, and do not reflect the official policy or position of the U.S. Government, the Department of Defense or the Department of the Air Force.
Author Disclosures: E.A. Fletcher: None. C.S. Lacey: None. S.A. Shah: None.
- © 2014 by American Heart Association, Inc.